01:00 PM EDT, 04/09/2024 (MT Newswires) -- Moderna ( MRNA ) shares rose 6% in recent Tuesday trading after results from an early study of the company's cancer vaccine mRNA-4157 showed the therapy benefited patients with a type of head and neck cancer.

According to data shared at the American Association for Cancer Research annual meeting, the vaccine, in combination with Merck's ( MRK ) Keytruda, was found to activate immune responses in patients.

Data from the 22 patients in the study also showed the combination was safe and well tolerated.

Merck ( MRK ) shares fell 0.5%.

Price: 111.38, Change: +6.29, Percent Change: +5.99